1. 1) Weatherall DJ. Cleeg JB. The clinical and molecular heterogeneity of the thalassemia syndromes.
Ann N Y Acad Sci. 1980;344:83-100.
2. 2) Huisman THJ, Carver MFH, Baysal E. Syllabus of Thalessemia Mutation. Augusta: The Sickle Cell Anemia Foundadion 1997; 1-30
3) Weatherall DJ, Clegg JB. The Thalassemia Syndromes, 4th edition, Oxford; Blackwell Scientific Publications, 2001;1760-1786
4) Banjerdpongchai R, Wilairat P, Fucharoen S, et. al. Morphological alterations and apoptosis of endotelial cells induced by thalassemic serum in vitro. Southeast Asian J Trop Med Public Health. 1997; 149-154
5) Butthep P, Khuhapinant A, Bunyaratvej A, et. al. Thallesemic serum inhibits endothelial cell mitosis in vitro. Southeast Asian J Trop Med Public Health. 1997; 155-160
6) Caro CG, Pedley TJ, Schroter RC, Seed WA. The Mechanics of the Circulation. New York, Oxford University Press, 1978; 243-349.
7) Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arteriel stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107:2864-2869
8) Kostis J, Lawrence-Nelson J, Ranjan R, Wilson A, Kostis W, Lacy C. Association of increased pulse pressure with the development of heart failure in SHEP. Systolic Hypertension in the Elderly (SHEP) Cooperative Research. Am J Hypertens. 2001;14:798-803
9) Mitchell GF, Pfeffer MA, Braunwald E, Rouleau J-L, Bernstein V, Geltman EM, Flaker GC. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. Circulation 1997;96:4254-60
10) YF Cheung, SY Ha, GCF. Ventriculo-vascular interactions in patients with beta- thalassaemia majör Chan Heart 2005; 91:769–773.
11) D. A. Stakos, A. Tavridou, D. Margaritis et al. Oxidised low-density lipoprotein and arterial function in beta-thalessemia majör. European Journal of Haematology 2009; 82 (477-483)
12) Lemogoum D, Van Bortel L, Najem B, et. al. Arterial Stiffness and wave reflections in patients with sicklecell disease. Hypertension 2004; 44;924-9
13) Latham RD, Westerhof N, Sipkema P, Rubal BJ, Reuderink P, Murgo JP. Regional wave travel and reflections along the human aorta: a study with six simultaneous micromanometric pressures. Circulation 1985; 72: 1257–1269.
14) Aessopos, A. Farmakis, D. Tsironi, M. Diamanti–Kandarakis E, Matzourani M, Fragodimiri C. Endotelial function and arterial stiffness in sickle-thalassemia patients Atherosclerosis 2007;191:427-432
15) O’Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical applications of arterial stiffness:definitions and reference values. Am J Hypertens 2002;15:426-444.
16) Nigam A, Mitchell GF, Lambert J, Tardif JC. Relation between conduit vessel stiffness (assessed by tonometry) endotelial function (assessed by flow-mediated dilatation) in patients with and without coronery hearth disease. Am J Cardiol 2003; 92:395-9
17) Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endotelium- dependent arterial relaxation by lysolecitin in modified low-dencity lipoproteins. Nature 1990; 344:160-2
18) Duffy SJ, Biegelsen ES, Holbrook M, et. al. Iron chelation improves endotelial function in patients with coronery artery disease. Circulation 2001; 103:2799-2804
19) Franklin SS, Larson MG, Khan SA, Wong ND, Kannel WB, Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103:1245–1249
20) Kass DA. Ventricular arterial stiffening: integrating the pathophysiology. Hypertension. 2005;
46:185-93.
21) Durier S, Fassot C, Laurent S et. al. Physiological genomics of human arteries: quantitative relationship between gene expression and arteriel stiffness. Ciculation 2003; 108:1845-51.